PROPHECI试验:口服焦磷酸盐治疗弹性假黄瘤的II期双盲安慰剂对照随机临床试验
PROPHECI是一项II期随机双盲安慰剂对照试验,评估每日口服焦磷酸盐补充对弹性假黄瘤患者异位钙化进展的疗效与安全性,主要终点为基线至治疗12个月非增强CT动脉钙化体积变化。
要点
- 弹性假黄瘤(PXE)与ABCC6基因变异及血浆焦磷酸盐(PPi)浓度低相关,目前无参考治疗。
- PROPHECI是首个评估每日口服PPi盐补充治疗PXE的II期随机双盲安慰剂对照试验。
- 主要终点为基线至12个月非增强CT动脉钙化体积变化,次要终点包括眼、皮肤病变及生活质量。
核心结论
- PROPHECI试验旨在提供每日口服PPi减少或稳定PXE异位钙化的安全性和有效性数据。
- 该试验还旨在验证未来PXE及其他亲本疾病治疗试验设计应纳入的最佳标志物。
研究设计与样本
- PROPHECI是一项II期随机双盲安慰剂对照临床试验(NCT04868578),评估每日口服PPi盐补充对PXE患者异位钙化进展的疗效和安全性。
- 主要终点为基线至治疗12个月经非增强CT扫描量化的动脉钙化体积变化。
- 次要终点包括每日口服PPi对眼和皮肤病变的安全性和有效性以及患者生活质量评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: /aims. Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6 gene are associated with low plasma pyrophosphate (PPi) concentration. There is currently no reference treatment for this chronic debilitating disease. METHODS: PROPHECI (PyROphosPHate supplementation to fight ECtopIc calcification in PseudoXanthoma Elasticum) is the first phase II, randomized, double-blind, placebo-controlled clinical trial (NTC 04868578) to evaluate the efficacy and safety of a daily oral PPi salt supplementation to attenuate and/or stabilize the progression of ectopic calcification in PXE patients. The primary endpoint is the change in arterial calcification volume quantified by non-contrast CT scan between baseline and 12 months of treatment. Secondary endpoints include the safety and efficacy of daily oral PPi administration on ocular and skin lesions and the evaluation of patients' quality of life. DISCUSSION: The PROPHECI trial aims to provide safety and efficacy data on the use of daily oral PPi to reduce or stabilize ectopic calcification in PXE. It also aims to validate the best markers to include in the design of future trials for the treatment of PXE and other parent diseases. TRIAL REGISTRATION: Trial registration number: NCT04868578. References can be found on the ClinicalTrials.gov website: https://clinicaltrials.gov/study/NCT04868578?cond=Pseudoxanthoma%20Elasticum&intr=pyrophosphate&rank=2.
引用
- Clotaire L, Rubera I, Duranton C, et al. The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate. Trials. 2025. PMID: 39881395. doi:10.1186/s13063-024-08666-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。